RSS Feed Print
Montelukast, Parkinsons and Lewy Body Dementia
Larrytherunner
Posted: Tuesday, October 13, 2020 4:36 PM
Joined: 2/26/2016
Posts: 224


I first read in January 2016 on line in The Guardian about Dr Ludwig Aigner's research in Austria using montelukast to treat animal models of Alzheimers..

The main points that I got from his research was that:

1. Montelukast blocks cysteine leukotrienes from entering at certain cell receptor sites, which prevents these molecules from signaling for the production of inflammatory substances inside the cells.

2. Cysteine leukotrienes make the blood brain barrier (BBB) more permeable. Therefore blocking leukotrienes makes the weakened BBB stronger. A weakened BBB is a characteristic of Alzheimers and age related dementias. 

3. The older laboratory rats improved in their mental obstacle tests, indicating the possibility that this drug could slow down or reverse the brain aging process in humans.

4. There was new neuron growth in certain parts of the aging lab animals brains, which lead to asking if this could also happen in humans.

The Guardian article

https://www.theguardian.com/science/2016/jan/08/alzheimers-treatment-closer-as-brain-inflammation-shown-to-be-key

Since Dr Aigner's Alzheimers research in 2015, there have been other research with montelukast for Parkinsons Disease and Lewy Body Dementia. Both diseases have similarities with Alzheimers in that they have increased neuroinflammation and weak blood-brain-barriers, conditions that montelukast is able to treat.

Lewy body dementia

https://alz-journals.onlinelibrary.wiley.com/doi/10.1016/j.jalz.2017.06.233

Parkinson disease

https://pubmed.ncbi.nlm.nih.gov/28178069/

Dr Aigner's research led to the montelukast Alzheimers clinical trial by Intelgenx in Canada started in 2018, and later the Emory University montelukast Alzheimers trial in Atlanta, Georgia.

Although both trials have been put on hold because of Covid-19, I expect that they should be getting positive results in 2021 and FDA approval for Alzheimers at higher doses up to 40 mg a day. Once there is FDA approval, physicians can start using montelukast for Alzheimers as well as off label for Parkinsons and Lewy Body Dementias. I believe it will a standard treatment for age-related dementias in a few years.


Larrytherunner
Posted: Tuesday, October 13, 2020 5:02 PM
Joined: 2/26/2016
Posts: 224


I have been taking montelukast for more than four years and have started a website on the latest research on repurposing this drug for Alzheimers and other medical conditions.

https://www.montelukast-repurposed.org/


Iris L.
Posted: Monday, October 19, 2020 8:06 PM
Joined: 12/15/2011
Posts: 16642


Good for you, Larry!  Thanks for providing information for us.  

Iris


Genericuser8888
Posted: Tuesday, November 10, 2020 5:57 PM
Joined: 4/4/2019
Posts: 5


This is great Larry!  I think there are a lot more links you could cite.  Keep up the good work.

 

https://biotuesdays.com/2020/11/09/intelgenx-reports-montelukast-effect-on-neurological-aging-published-in-peer-reviewed-journal/

https://biotuesdays.com/2018/02/13/2018-2-9-strong-scientific-rationale-for-intelgenx-montelukast-program/

 

This report from a year or two ago contains a ton of links that might help buff up your site.

http://www.upshawdc.com/pubs/igxtarticlerev3.pdf


Larrytherunner
Posted: Thursday, November 12, 2020 11:50 AM
Joined: 2/26/2016
Posts: 224


Thanks for the encouragement and the information.  I did not include the Norwegian studies because it was based on the FDA approved dosage 10 mg per day for asthma, which is too small to show clear effectiveness in preventing Alzheimers. The studies showed a very small reduction in Alzheimers diagnoses. If Merck had chosen twice a day dosing for asthma for adults, the reduction in Alzheimers diagnoses likely would have been much greater and there would have been clearer evidence that montelukast prevented or delayed Alzheimers.